Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France.

The new facility will allow Sanofi's vaccines unit, Sanofi Pasteur, to expand the supply of influenza vaccine VaxigripTetra, which is compliant with the World Health Organization's recommendation.

Sanofi plans to complete the expansion by 2021, subject to regulatory approvals, and will commence vaccine production in the new facility in 2022.

Sanofi Pasteur remains the sole influenza vaccine producer in France.